pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,053 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1788Endpoints1392Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Sanofi proposes to cease negative statements about CSL's flu vaccine amid EU probe
    Sanofi has offered to stop making disparaging comments about CSL's flu vaccine following an investigation launched by the European Commission. The offer comes two weeks after the Commission began p…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • FDA clears first over-the-counter glucose monitor for children 2 and older
    The FDA cleared Dexcom's Stelo continuous glucose monitor for over-the-counter sale, allowing children age 2 and up to obtain the device without a prescription. The agency says real-time glucose d…
    STAT · 4mo agoRegulatoryNeutral↗ source
← prev
page 114 of 163
next →
111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
  • RFK Jr. moves to compile list of Covid-19 vaccine injuries to streamline compensation claims
    Health secretary Robert F. Kennedy Jr. announced plans to create a list of injuries that would be presumed caused by Covid-19 vaccines. The list would allow individuals who suffer from those condi…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Longevity entrepreneur Bryan Johnson reveals he has autoimmune gastritis, a hard-to-diagnose stomach disease
    Bryan Johnson, known for his longevity ventures, announced on X that he has been diagnosed with autoimmune gastritis. The condition is a chronic inflammatory disease where antibodies attack stomac…
    STAT · 4mo agoNeutral↗ source
  • Vertex to acquire endocrinology startup Crinetics for $10 billion, signaling push into new therapeutic areas
    Vertex Pharmaceuticals announced a $10 billion cash purchase of Crinetics, an endocrinology-focused biotech. The deal represents the largest acquisition in Vertex’s history and underscores its pla…
    Endpoints · 4mo agoDealPositive↗ source
  • Vera Therapeutics receives accelerated approval for Trutakna to treat IgA nephropathy
    Vera Therapeutics announced that its fusion protein atacicept, branded as Trutakna, has been granted accelerated approval by the FDA for the treatment of immunoglobulin A nephropathy, a chronic aut…
    Endpoints · 4mo agoApprovalPositive↗ source
  • FDA greenlights Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has approved a new therapy from Vera Therapeutics aimed at treating IgA nephropathy, a chronic autoimmune kidney disorder. The drug, called Trutakna, is intended for patients with this con…
    STAT · 4mo agoApprovalPositive↗ source
  • Vertex to acquire Crinetics in $10 billion deal, expanding rare endocrine disorder pipeline
    Vertex announced on July 7, 2026 that it will acquire Crinetics Pharmaceuticals for $10 billion, marking the company’s largest-ever transaction. Crinetics is a biotech focused on developing treatm…
    STAT · 4mo agoDealNeutral↗ source
  • Vertex to acquire Crinetics in $10 billion deal, adding rare-disease drug Palsonify to its portfolio
    Vertex Pharmaceuticals announced a $10 billion transaction to purchase Crinetics Pharmaceuticals. The deal will bring Crinetics' recently launched drug Palsonify into Vertex's portfolio. Palsonify…
    STAT · 4mo agoDealPositive↗ source
  • FDA grants accelerated approval to Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has granted accelerated approval to Trutakna (formerly known as atacicept) from Vera Therapeutics for adult patients with IgA nephropathy, a chronic kidney disease that can progress to rena…
    BioPharma Dive · 4mo agoApprovalPositive↗ source
  • Vertex to buy Crinetics for $10 billion, expanding into endocrine disease drugs
    Vertex announced an agreement to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying $85 per share. The purchase brings two recently launched drugs for a rare hormonal disorder into…
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • CMS launches ACCESS program to reward Medicare digital health solutions that improve outcomes
    The Centers for Medicare & Medicaid Services introduced the ACCESS program, a new initiative that invites digital health companies to participate in Medicare. The program ties Medicare payments to…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipeline
    Oberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trial
    Kailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
    BioPharma Dive · 4mo agoPositive readoutNeutral↗ source
  • STAT newsletter highlights the decline of employer-based health insurance in the U.S.
    John Wilkerson, a Washington correspondent for STAT, writes the D.C. Diagnosis newsletter that focuses on health policy. In this edition he turns his attention to the weakening of the employer-base…
    STAT · 4mo agoNegative↗ source
  • Hengrui and Kailera's oral GLP-1 pill shows promising efficacy but notable side effects in Chinese obesity and diabetes trials
    Hengrui Pharma and Kailera Therapeutics reported results from two late‑stage trials in China, one targeting obesity and the other diabetes, using their daily oral GLP‑1 pill. The studies demonstrat…
    Endpoints · 4mo agoPositive readoutNeutral↗ source
  • STAT+ warns that employer-sponsored health insurance is deteriorating, leaving workers and businesses exposed
    Bob Herman's latest STAT+ newsletter introduces a new series called Out of Pocket, Out of Reach, which will examine how the employer-based health-insurance system is falling apart. The article not…
    STAT · 4mo agoNegative↗ source
  • Novartis, Vertex and Ipsen announce new acquisitions as M&A activity surges in early July 2026
    Biopharma’s merger and acquisition engine remains robust, with four companies revealing new deals within the first six days of July. The announcements add to a total of 45 acquisitions reported in…
    Endpoints · 4mo agoDealPositive↗ source
  • MeiraGTx secures $135 million royalty deal with Oberland Capital
    MeiraGTx announced a royalty financing agreement with Oberland Capital. The deal provides the gene-therapy company with an initial $135 million, including a $10 million equity investment from Oberl…
    Endpoints · 4mo agoDealPositive↗ source
  • Secret shopper study examines GLP-1 prescribing practices on telehealth platforms
    STAT Health Tech newsletter reports a secret shopper study that evaluated how telehealth sites prescribe GLP-1 drugs. The study involved researchers posing as patients to assess prescribing behavi…
    STAT · 4mo agoNeutral↗ source
  • Ebola outbreak highlights gaps in response system
    The recent Ebola outbreak has underscored serious shortcomings in the global and national mechanisms designed to detect and contain emerging infections. Analysts note that the fragmented response…
    STAT · 4mo agoNegative↗ source
  • Small U.S. Businesses Struggle to Provide Health Insurance as Coverage Rates Slip
    America's employer-based health insurance system is becoming unsustainable for small businesses, which form the backbone of many communities. The share of working-age adults receiving coverage thr…
    STAT · 4mo agoNegative↗ source
  • Ebola outbreak in eastern DRC risks becoming a never-ending crisis, experts warn
    Ivan Buendia Gayton, a technologist and humanitarian adviser, and Eric D. Perakslis, an engineer and former MSF strategic adviser, co‑author an opinion piece on the latest Ebola flare‑up in eastern…
    STAT · 4mo agoNegative↗ source
  • Tampa General Hospital sues Eli Lilly over 340B discount halt
    Tampa General Hospital filed a lawsuit against Eli Lilly, alleging the drugmaker stopped providing 340B program discounts to the hospital. The dispute centers on Lilly's new requirement that hospi…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Compass Pathways reports six-month durability of response in pivotal psilocybin depression trial
    Compass Pathways announced that patients in the second of its two pivotal psilocybin trials for depression continued to show a therapeutic response for at least six months. The durability data sugg…
    Endpoints · 4mo agoPositive readoutPositive↗ source